The Company will initially focus on advancing its unique, orally available, synthetic flavanol for the treatment of BMD. The Food and Drug Administration (FDA) has granted Orphan Drug designation to EB 002 ((+)-epicatechin; Epirium Bio) for the treatment of Duchenne and Becker muscular dystrophy. Duchenne and Becker muscular dystrophy […]
Click here to view original web page at www.neurologyadvisor.com